Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation.

Med (New York, N.Y.)·2026

Same author

Cancer-Related Cognitive Impairment in Breast Cancer: Current State of Knowledge, Mechanisms, Diagnosis, Prevention and Treatment.

Cancers·2026

Same author

Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes.

Cancer treatment reviews·2026

Same author

Solitary Testicular Metastasis From Ductal Prostate Cancer 5 Years After Radical Prostatectomy: A Case Report.

Case reports in urology·2026

Same author

Ocular Toxicities of Anticancer Therapies in the Era of Precision Oncology: A Practical, Clinically Oriented Narrative Review.

Biomedicines·2026

Same author

Incidental detection of PDAC via <sup>18</sup>F-PSMA PET/CT in a patient with recurrent prostate cancer. A case report.

Frontiers in nuclear medicine·2026

Search research articles

Related Experiment Video

Updated: Jul 30, 2025

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Low-Dose Immunotherapy: Is It Just an Illusion?

Fausto Meriggi¹, Alberto Zaniboni¹, Anna Zaltieri²

¹Oncology Department, Poliambulanza Foundation Hospital Institute, Via Leonida Bissolati 57, 25124 Brescia, Italy.

|May 16, 2023

Summary

Reducing immunotherapy dosage may maintain cancer treatment effectiveness while lowering costs. This approach could expand patient access to vital onco-haematological therapies.

Keywords:

financial toxicity immunotherapy low-dose

More Related Videos

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Published on: July 22, 2011

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Related Experiment Videos

Last Updated: Jul 30, 2025

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Published on: July 22, 2011

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Area of Science:

Oncology
Pharmacology
Immunology

Background:

Immunotherapy has revolutionized onco-haematological treatment outcomes over the past decade.
Managing novel adverse events and escalating costs are significant challenges with current immunotherapy protocols.

Purpose of the Study:

To evaluate the feasibility of reducing immunotherapy dosage without compromising efficacy.
To analyze the economic implications and potential for wider patient access through dose reduction.

Main Methods:

Review of pharmacokinetic and pharmacodynamic data related to immunotherapies.
Analysis of recent scientific literature supporting the use of reduced immunotherapy doses.

Main Results:

Emerging evidence suggests that lower immunotherapy doses may be as effective as standard doses.
Dose reduction could significantly decrease treatment costs associated with immunotherapy.

Conclusions:

Lower-dose immunotherapy presents a viable strategy to mitigate costs and improve accessibility for cancer patients.
Further research into optimized dosing regimens is warranted to balance efficacy, safety, and cost-effectiveness.